Clinical stage biopharmaceutical company DiscGenics has completed patient enrolment in its Phase I / Phase II first-in-human US clinical study of injectable discogenic cell therapy (IDCT) to treat degenerative disc disease (DDD).

The allogeneic therapy uses proprietary discogenic cells, which are biomedically engineered progenitor cells derived from intervertebral disc tissue.

DiscGenics’ study aims to analyse the safety and preliminary efficacy of IDCT in patients with symptomatic, single-level, mild to moderate lumbar intervertebral disc degeneration.

The company claimed that no safety issues have been reported to date in any of the 60 subjects treated under the prospective, randomised, double-blinded, vehicle and placebo-controlled multi-centre clinical study.

Subjects of the trail have been screened and verified to have met all eligibility criteria for enrolment, including early to moderate symptomatic, single-level DDD from L3-S1, and no previous lumbar spine surgery.

Safety and reduction in pain are cited as the primary outcome measures of the trail. The secondary outcome measures include a decrease in disability and radiographic improvement.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

DiscGenics board of directors CEO and chairman Flagg Flanagan said: “The completion of patient enrolment in our first-in-human US study of IDCT for DDD represents a significant milestone and an important step in the development of this potentially revolutionary treatment for a truly significant unmet medical need.

“We are looking forward to successful completion of the study. In the meantime, we are focused on the scale-up and scale-out of our commercial cGMP manufacturing facility in Salt Lake City to meet all regulator requirements and anticipated commercial demand for IDCT.”

The trial is currently in progress in 14 centres across 12 US states.

IDCT is also being analysed in a multi-centre safety study in Japan supported by a Clinical Trial Notification. It is approved by the Japanese Pharmaceuticals and Medical Devices Agency (PMDA).